Discovery cohortα | Validation cohortβ | ||
---|---|---|---|
Number of RA patients/samples | 64/128 | 12/12 | |
Sex of RA patients (female/male) | 44/20 | 9/3 | |
Visit 1 | Visit 2 | – | |
DAS28-CRP | |||
Mean ± SD | 3.1 ± 1.3 | 3.0 ± 1.4 | 2.4 ± 1.3 |
Range (min–max) | 1.5–7.0 | 1.2–6.6 | 1.7–5.9 |
Age (years) | |||
Mean ± SD | 62.7 ± 10.5 | 63.5 ± 10.6 | 67.8 ± 10.6 |
Range (min–max) | 32–85 | 33–86 | 54–84 |
BMI | |||
Mean ± SD | 30.6 ± 5.7 | 31.1 ± 6.2 | 27.0 ± 4.1 |
Range (min–max) | 22.4–45.3 | 22.8–47.8 | 19.0–33.3 |
N/A (n) | 6 | 6 | 2 |
Smoking history (n) | |||
Current (active within 3 months) | 7 | 5 | 1 |
Former | 31 | 32 | 3 |
Never | 25 | 27 | 7 |
N/A | 1 | 0 | 1 |
CRP (mg/L) | |||
Mean ± SD | 8.91 ± 16.8 | 8.0 ± 12.7 | 11.5 ± 21.7 |
Range (min–max) | 0.29–113.0 | 0.7–84.0 | 1.0–77.1 |
RFγ (n) | |||
Positive | 36 | – | 6 |
Negative | 15 | – | 2 |
N/A | 13 | – | 4 |
Anti-CCPγ (n) | |||
Positive | 44 | – | 5 |
Negative | 13 | – | 1 |
N/A | 7 | – | 6 |
Treatment | |||
Methotrexate use (n (%)) | 48 (75.0%) | 49 (76.6%) | 7 (58.3%) |
Methotrexate dose (mg/week) | |||
Median | 20.0 | 20.0 | 22.5 |
IQR [Q1, Q3] | [15.0, 25.0] | [15.0, 25.0] | [17.5,25.0] |
Prednisone use (n (%)) | 29 (45.3%) | 28 (43.8%) | 4 (33.3%) |
Prednisone dose (mg/day) | |||
Median | 5.0 | 5.0 | 5.0 |
IQR | [5.0, 7.0] | [5.0, 5.0] | [5.0, 5.0] |
TNFi-bDMARDsδ (n (%)) | 23 (35.9%) | 21 (32.8%) | 3 (25.0%) |
Non-TNFi-bDMARDsε (n (%)) | 6 (9.4%) | 7 (10.9%) | 1 (8.3%) |
Non-methotrexate csDMARDsλ (n (%)) | 20 (31.2%) | 27 (42.2%) | 1 (8.3%) |